PGM2L1

Across TCGA pan-cancer cohorts, PGM2L1 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated PGM2L1 data layer compared with 4 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PGM2L1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PGM2L1 expression acts as an unfavorable survival marker, although some lineages such as KIRC and UCS show a favorable association.

MESO, ACC, and BLCA are the cancer types where PGM2L1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Quartile	II,III,IV	0.286	0.681	<.001	96	view →
ACC	DFS	Median	All	0.187	0.729	<.001	90	view →
BLCA	DFS	Tertile	All	0.222	0.488	.002	70	view →
LIHC	OS	Median	All	0.593	0.782	<.001	55	view →
STAD	DFS	Median	All	0.321	0.595	.004	42	view →
KIRC	OS	Quartile	All	0.720	0.532	.002	36	view →
LUAD	OS	Quartile	All	0.338	0.619	<.001	35	view →
UCS	OS	Median	IV	0.752	0.404	.013	30	view →
PAAD	DFS	Tertile	All	0.167	0.442	.005	29	view →
BRCA	OS	Tertile	IV	0.927	0.335	.001	21	view →
CHOL	OS	Tertile	All	0.223	0.773	.001	21	view →
THYM	OS	Tertile	All	1.000	0.723	.003	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

PGM2L1–MESO (OS)

Open the MESO breakdown →